Eris Lifesciences enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


16,116	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
238	54.7	205	94.2	86.0
−2.8	−7.0	417	636	24.7
2,310	2,310	2,478	2,735	830
18,185	—	—	—	—
2,072	2,255	2,273	2,641	744
₹1,312.97	—	—	—	—

6,451	6,205	5,750	5,957	3,051
35.8%	37.2%	43.1%	45.9%	27.2%
0.13×	—	—	—	—

5.46×	—	—	—	—
15.67×	—	—	—	—
20.77×	—	—	—	—
75.41×	—	—	—	—
3,330	3,129	2,894	2,009	1,685
1,161	1,120	1,017	675	537
875	841	702	492	420
—	538	1,065	486	292
241	241	910	357	−550
—	241	876	351	−551
—	297	155	129	841

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ERIS₹1,163.60

Eris Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersMANKIND AJANTPHARM TORNTPHARM EMCURE GRANULES CONCORDBIO INDGN CAPLIPOINTMcap ₹16,116 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	16,115.9
- Cash, Equiv & ST Investments	86.0	94.2	204.7	54.7	238.1
+ Minority Interest	24.7	635.9	417.4	-7.0	-2.8
+ Total Debt	830.0	2,735.3	2,477.9	2,309.7	2,309.7
Enterprise Value	—	—	—	—	18,184.7
Net Debt (memo)	744.0	2,641.0	2,273.2	2,254.9	2,071.6
EV per Share	—	—	—	—	1,312.97

Total Capital	3,050.7	5,957.3	5,749.7	6,205.3	6,451.3
Total Debt/Total Capital	27.21	45.91	43.10	37.22	35.80
Total Debt/EV	—	—	—	—	0.13

EV/Sales	—	—	—	—	5.46
EV/EBITDA	—	—	—	—	15.67
EV/EBIT	—	—	—	—	20.77
EV/Free Cash Flow	—	—	—	—	75.41
Reference Items — Trailing FY Values
Sales	1,685.1	2,009.1	2,893.6	3,129.4	3,329.6
EBITDA	536.7	674.8	1,017.2	1,120.1	1,160.8
EBIT	419.7	492.2	701.7	840.6	875.4
Operating Cash Flow	291.7	486.0	1,065.0	538.0	—
Free Cash Flow	-549.7	356.8	910.0	241.1	241.1
FCFF (free cash flow to the firm)	-551.4	350.7	876.1	241.1	—
Capital Expenditure	841.4	129.2	155.0	296.9	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.